Eko Health pricing

About

Eko Health makes FDA-cleared AI that detects cardiac and pulmonary disease during a routine physical exam. Founded in 2013 by three UC Berkeley students — Connor Landgraf (CEO), Jason Bellet (COO), and Tyler Crouch (CTO) — the San Francisco company set out to modernize the stethoscope, a tool that had barely changed in 200 years. Its first digital stethoscope cleared the FDA in 2015; today its software layers AI algorithms (developed and validated with partners including Mayo Clinic and Imperial College London) that flag structural heart murmurs, atrial fibrillation, and low ejection fraction in seconds. Eko says its platform is used by more than 500,000 healthcare professionals.

The business pairs hardware (digital stethoscopes you buy outright) with recurring software (the Eko+ subscription that unlocks the AI) and an enterprise platform (SENSORA) for health systems. Eko has raised over ~$165M, most recently a $41M Series D in June 2024 (ARTIS Ventures, Highland Capital Partners, Questa Capital, and Mayo Clinic among backers), to scale AI-driven heart and lung disease detection internationally.

For the most current information, visit Eko Health.

Pricing summary : How Eko Health’s pricing model works

Eko Health runs a hybrid hardware + SaaS model with a separate enterprise platform. First you buy a device once: the CORE Digital Attachment at $259 (it clips onto an analog stethoscope), the 3M Littmann CORE at $379, or the flagship CORE 500 at $449 (MSRP $499; all three are frequently discounted — $224 / $329 / $399 respectively at capture). Then, to turn on the FDA-cleared AI, you subscribe to Eko+ at $12.99/month or $119.99/year (the annual works out to about $9.99/month billed upfront). A free Eko Standard tier gives amplification, audio filters, live waveform trace, and record/save/share — but no AI. Veterinary users get Eko Vet+ at $180/year. Every device ships with a 14-day Eko+ trial.

For hospitals and health systems, Eko sells the SENSORA platform and Eko Telehealth on a custom quote. SENSORA is where the model gets interesting: its Category III CPT code 0962T (effective July 1, 2025) and the finalized CMS OPPS payment of roughly $128.90 per use (APC 5734) mean a hospital can be reimbursed by insurers every time the algorithm screens a patient — turning AI screening into a billable, per-exam clinical service.

What makes this different: the hardware is a near-commodity entry point, and the AI — the actual product — is gated behind a low-cost subscription and an enterprise platform whose unit economics are tied to a reimbursement code, not a seat. The device gets the tool in a clinician’s hands; the recurring revenue comes from Eko+ and, at scale, from per-exam reimbursement.

Pricing by product

Sales motions across products: self-serve PLG for hardware and Eko+ (buy on the store, start a trial, subscribe), and sales-led for the SENSORA platform and Eko Telehealth, where deployment, EHR integration, training, and per-exam reimbursement are negotiated per health system.

Hidden costs : What Eko Health users actually pay

The sticker on the box is only the start. A clinician who buys a CORE 500 and wants the AFib/murmur AI is really committing to device + annual software — and the software renews indefinitely. Skip Eko+ and the expensive device degrades into a (very good) amplified stethoscope with no disease detection. That coupling is the real cost structure.

Other things to budget for: the AI is subscription-gated, so the recurring $119.99/yr is effectively mandatory to use the headline feature; AFib detection requires the $449 CORE 500 specifically (the cheaper devices can’t do it regardless of subscription); and at the health-system level the economics invert — SENSORA is a quoted contract, but each exam is reimbursable at ~$128.90 under CPT 0962T, so the “cost” can be offset (or net-positive) through billing rather than paid out of pocket.

Want to estimate your own Eko Health cost? Use the Eko Health pricing calculator to model device + subscription spend across your team.

Pricing evolution : Eko Health pricing history and changes

Cadence

Tracked range: 2015–present, anchored on FDA-clearance milestones, the June 2023 CORE 500 launch, the June 2024 Series D, the July 2025 CPT code, the December 2025 CMS finalization, and the live 2026-06-10 store capture.

Notable changes

• 2015 — First FDA clearance for the CORE attachment; the business is a one-time hardware sale with no AI subscription.
• 2023-06 — CORE 500 launches at $449 (MSRP $499) with a 3-lead ECG and full-color display, anchoring the premium tier and pairing with Eko+ for AI.
• 2024-06 — $41M Series D (total funding past ~$165M) to scale AI detection and the SENSORA platform internationally.
• 2025-07 — CPT code 0962T takes effect, making AI-assisted cardiac analysis on SENSORA a billable procedure.
• 2025-12 — CMS finalizes national OPPS payment for SENSORA at roughly $128.90 per use (APC 5734) — per-exam reimbursement goes national.
• 2026-06 — Live capture: CORE Attachment $259, Littmann CORE $379, CORE 500 $449 (all discounted), Eko+ $12.99/mo or $119.99/yr, Eko Vet+ $180/yr, SENSORA + Telehealth quoted.

What’s unique : Eko Health’s distinctive pricing mechanics

1. Hardware as the wedge, AI as the subscription. The stethoscope is a one-time, near-commodity purchase ($259–$449) that lands the device in a clinician’s hands; the recurring revenue comes from Eko+ ($119.99/yr) that unlocks the disease-detection AI. The expensive object is the cheap part of the relationship over time — a razor-and-blades structure built around an FDA-cleared algorithm.

2. A hardware gate on a software feature. AFib detection requires the CORE 500 specifically — the cheaper Littmann CORE and CORE Attachment can’t do it even with an Eko+ subscription. Eko uses the embedded 3-lead ECG to justify the premium device price while making the most clinically compelling AI feature exclusive to it.

3. Per-exam reimbursement as the enterprise meter. SENSORA’s pricing is anchored to CPT code 0962T and a CMS payment of ~$128.90 per use — so the health-system tier is effectively metered by billable exams, not seats or sites. Few software companies can say the government set a per-use price for their product; that reimbursement turns Eko’s AI from a cost line into a revenue line for the hospital.

Strengths & weaknesses

Billing UX : Eko Health billing controls and transparency

• Billing controls — Hardware is a one-time card checkout on the Eko store; Eko+ is a self-serve subscription you can pay monthly ($12.99) or annually ($119.99) with flexible cancellation on the monthly plan. Every device includes a 14-day Eko+ trial that auto-renews into the paid plan, and a free Eko Standard tier is always available if you don’t want the AI.
• Usage visibility — Eko+ ships a web dashboard, patient profiles, PDF reports, and secure file sharing, so clinicians can see and share their AI results. At the health-system level, SENSORA integrates with EHRs and adds user management and SSO for centralized oversight, plus the reimbursement workflow tied to CPT 0962T.
• Payment options — Card-based self-serve (with buy-now-pay-later financing offered on devices) for individuals; SENSORA and Eko Telehealth are invoiced under negotiated enterprise contracts with on-site training and VIP support. Per-exam reimbursement is handled through the hospital’s normal CMS/insurer billing.

Strategic wins : Why Eko Health’s pricing decisions worked

1. Razor-and-blades around an FDA-cleared algorithm

Selling the stethoscope once and the AI forever turns a hardware company into a recurring-revenue software business. The device ($259–$449) is the acquisition cost; Eko+ ($119.99/yr) is the durable margin. Because the AI is FDA-cleared and clinically validated, the subscription is defensible in a way a generic SaaS add-on wouldn’t be. See how AI companies structure pricing.

2. Letting the government price the enterprise tier

By securing CPT code 0962T and a national CMS payment (~$128.90/use), Eko made SENSORA reimbursable. That reframes the enterprise sale from “buy our software” to “deploy a screening service you can bill for” — arguably the strongest possible answer to healthcare’s cost objection. Related: outcome-based pricing trends.

3. Gating the marquee AI to the premium device

Tying AFib detection to the $449 CORE 500 gives clinicians a concrete reason to buy up. It couples a hardware upgrade to a software capability, lifting average device revenue without changing the subscription price. See choosing the right usage metric.

Areas to improve : Gaps in Eko Health’s pricing approach

1. The subscription gate can feel like a bait-and-switch

A clinician who pays $449 for a CORE 500 then discovers the headline AI requires another $119.99/year may feel the device was sold incompletely. Surfacing the full device-plus-Eko+ cost of ownership up front — rather than at the trial’s end — would set expectations and reduce churn. See bill shock and cost unpredictability.

2. No published enterprise anchor

SENSORA and Eko Telehealth are entirely quote-driven. Health systems can’t self-qualify or budget without a sales call, and the absence of even an indicative per-site or per-exam list price slows mid-market adoption. A published reference price (even a range) would shorten the funnel.

3. Feature fragmentation across devices

Whether you get AFib detection depends on which device you bought, not just whether you subscribe. That device/feature matrix is hard for buyers to reason about and risks under-selling cheaper devices to clinicians who later discover the AI they wanted is gated to hardware they don’t own.

Key takeaways

1. Hardware lands, software earns. Eko sells a $259–$449 device once and monetizes the FDA-cleared AI through a $119.99/yr subscription — a razor-and-blades model with a regulatory moat.
2. A reimbursement code is the ultimate price anchor. SENSORA’s CPT 0962T and ~$128.90 CMS payment let hospitals bill per exam, turning Eko’s enterprise tier into a self-funding clinical service.
3. Gate features to hardware to lift device revenue. AFib detection is exclusive to the $449 CORE 500, giving clinicians a reason to buy the premium device.
4. Free tiers keep the ecosystem warm. Eko Standard (no AI) and a 14-day Eko+ trial keep non-subscribers inside the platform and primed to upgrade.
5. Healthtech monetization increasingly runs through reimbursement, not seats. Eko’s per-exam model shows how AI clinical tools can price against billable procedures rather than software licenses.

UBP implications

1. Per-use reimbursement is a usage meter set by a third party. When a payer assigns a per-exam price (CPT 0962T at ~$128.90), the vendor’s enterprise tier becomes inherently usage-based — and the buyer’s cost is offset by billing. That’s a powerful template for any AI tool that produces a billable clinical artifact. See usage-based pricing strategy.
2. Subscriptions can unlock value the hardware merely enables. Eko shows you can sell the instrument cheaply and meter the intelligence — the recurring charge attaches to the AI output, not the object. See choosing the right usage metric.
3. Regulatory clearance is pricing power. FDA clearance and clinical validation make a software subscription defensible where a generic add-on would face discount pressure — the moat justifies the recurring fee.

Sources

• Eko Health memberships page (live capture, accessed 2026-06-10)
• Eko Health stethoscope store (live capture, accessed 2026-06-10)
• Eko CORE 500 product page (live capture, accessed 2026-06-10)
• Eko+ monthly membership page ($12.99/mo, $119.99/yr; accessed 2026-06-10)
• Eko Health raises $41M Series D (MassDevice) (accessed 2026-06-10)
• Eko Health launches CORE 500 (PR Newswire) (accessed 2026-06-10)
• CMS finalizes OPPS payment for SENSORA (PR Newswire) (accessed 2026-06-10)
• Eko Health granted Category III CPT code for SENSORA (accessed 2026-06-10)
• Eko Health Inc. — Wikipedia (accessed 2026-06-10)

Bottom line

Eko Health is a hybrid hardware + SaaS healthtech company: buy an FDA-cleared digital stethoscope once ($259 CORE Attachment, $379 3M Littmann CORE, or $449 CORE 500), then subscribe to Eko+ ($12.99/month or $119.99/year) to unlock the AI that detects murmurs, AFib, and low ejection fraction — with a free Eko Standard tier (no AI) and Eko Vet+ at $180/year. For health systems, the quoted SENSORA platform is the strategic engine: its CPT code 0962T and finalized CMS payment of ~$128.90 per exam make AI cardiac screening a billable, per-use clinical service. The device lands the customer; the subscription and per-exam reimbursement earn the revenue. Browse the pricing blueprint for more fully-researched company profiles.

Want to compare Eko Health against other healthtech and AI companies? Browse the pricing blueprint.

Pricing timeline : Major events on a vertical axis

Each milestone below corresponds to a public pricing change, product launch, or material adjustment. Major events use a filled marker; minor adjustments use a faded one.

Live capture — hardware + Eko+ + SENSORA hybrid

Jun 2026

Current public pricing: CORE Attachment $259 (sale $224), 3M Littmann CORE $379 (sale $329), CORE 500 $449 (sale $399); Eko+ software $12.99/mo or $119.99/yr (Eko Standard free, Eko Vet+ $180/yr); Eko Telehealth and SENSORA quoted via sales, SENSORA reimbursed per-exam under CPT 0962T.

CMS finalizes national OPPS payment (~$128.90/use)

Dec 2025

CMS finalizes national Outpatient Prospective Payment System payment for SENSORA, assigning CPT 0962T to APC 5734 at roughly $128.90 per use. Hospitals and outpatient settings can now be reimbursed per AI cardiac exam, cementing the per-use enterprise model.

SENSORA gets a billable CPT code (0962T)

Jul 2025

Category III CPT code 0962T for AI-assisted cardiac dysfunction analysis takes effect July 1, 2025, covering SENSORA exams. This converts AI screening from a software cost into a reimbursable clinical service for health systems — a structural shift in how the enterprise tier monetizes.

$41M Series D — scaling the SaaS + platform motion

Jun 2024

Eko raises a $41M Series D (bringing total funding past ~$165M, with ARTIS Ventures, Highland Capital, Questa Capital, and Mayo Clinic among backers) to scale AI-driven heart and lung disease detection and the SENSORA platform internationally.

CORE 500 launches at $449 with embedded AI + 3-lead ECG

Jun 2023

Eko launches the CORE 500 (MSRP $499, listed $449) — full-color display, 40x amplification, active noise cancellation, and a 3-lead ECG enabling on-device AFib detection. This anchors the high end of the hardware lineup and pairs with the Eko+ software subscription for AI.

First FDA clearance — CORE attachment, no recurring AI

Sep 2015

Eko's first digital stethoscope (the CORE attachment) clears the FDA. The early model is a hardware sale that digitizes and amplifies auscultation and streams audio to the Eko app — no AI disease-detection subscription yet. The business is essentially a one-time device sale.